Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical impacts and management of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a narrative review

  • Jisun Park (Department of Pediatrics, Inha University Hospital, Inha University College of Medicine) ;
  • Eun Young Joo (Department of Pediatrics, Inha University Hospital, Inha University College of Medicine) ;
  • Ji-Eun Lee (Department of Pediatrics, Inha University Hospital, Inha University College of Medicine) ;
  • Su Jin Kim (Department of Pediatrics, Inha University Hospital, Inha University College of Medicine)
  • Received : 2025.09.02
  • Accepted : 2025.10.10
  • Published : 2025.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence of pediatric urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) has increased worldwide; however, optimal empirical treatment strategies remain controversial. This review addresses the prevalence, virulence factors, clinical impacts, and antibiotic management of UTIs caused by ESBL-PE in children. The prevalence of ESBL-PE among pediatric UTI isolates exceeds 20% in many regions, including Korea. No significant differences exist in the clinical manifestations between ESBL(+) UTIs and other UTIs. Despite in vitro resistance, third-generation cephalosporins frequently achieve therapeutic success because of their high urinary drug concentrations. Based on the patient's condition and risk factors, an initial empirical antibiotic should be selected, and early de-escalation and carbapenem-sparing strategies are essential to balance treatment efficacy and resistance prevention. Therefore, Korean guidelines for the treatment of pediatric UTIs are required.

Keywords

Acknowledgement

This work was supported by Inha University Research Grant (2025).

References

  1. Mattoo TK, Shaikh N, Nelson CP. Contemporary management of urinary tract infection in children. Pediatrics 2021;147:e2020012138.
  2. Gnech M, Bujons A, Radmayr C, 't Hoen L, Bogaert G, Burgu B, et al. Update and summary of the EAU/ESPU paediatric guidelines on urinary tract infection in children. J Pediatr Urol 2025 Jun 24 [Epub]. https://doi.org/10.1016/j.jpurol.2025.06.016
  3. Nelson Z, Aslan AT, Beahm NP, Blyth M, Cappiello M, Casaus D, et al. Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement. JAMA Netw Open 2024;7:e2444495.
  4. Hari P, Meena J, Kumar M, Sinha A, Thergaonkar RW, Iyengar A, et al. Evidence-based clinical practice guideline for management of urinary tract infection and primary vesicoureteric reflux. Pediatr Nephrol 2024;39:1639-68.
  5. Lee SJ. Clinical guideline for childhood urinary tract infection (second revision). Child Kidney Dis 2015;19:56-64.
  6. Bryant PA, Bitsori M, Vardaki K, Vaezipour N, Khan M, Buettcher M, et al. Guidelines for complicated urinary tract infections in children: a review by the European Society for Pediatric Infectious Diseases. Pediatr Infect Dis J 2025;44:e211-23.
  7. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA, et al. Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis 2024 Aug 7 [Epub]. https://doi.org/10.1093/cid/ciae403
  8. Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. J Infect 2016;73:547-57.
  9. Wong SW, Tullus K, Chan YHE. Controversies in treating febrile infantile urinary tract infection caused by extended-spectrum beta-lactamase producing Enterobacteriaceae: an international multi-centre survey. Pediatr Nephrol 2025;40:2253-66.
  10. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005;52:323-9.
  11. Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect 2020;149:e12.
  12. Pai H. The characteristics of extended-spectrum beta-lactamases in Korean isolates of Enterobacteriaceae. Yonsei Med J 1998;39:514-9.
  13. Yoo YM, Park BS, Lee SY, Park KJ, Jung HJ, Pai KS. An epidemiologic study on hosts and pathogens of urinary tract infection in urban children of Korea (2012–2017). Child Kidney Dis 2019;23:29-35.
  14. Kim JH, Lee J, Kim DH, Park JY, Lee H, Kang HG, et al. Maternal antibiotic exposure during pregnancy is a risk factor for community-acquired urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in infants. Pediatr Nephrol 2022;37:163-70.
  15. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis 2015;15:414.
  16. Park SY, Kim JH. Clinical significance of extended-spectrum β-lactamase-producing bacteria in first pediatric febrile urinary tract infections and differences between age groups. Child Kidney Dis 2017;21:128-35.
  17. Kim YH, Yang EM, Kim CJ. Urinary tract infection caused by community-acquired extended-spectrum β-lactamase-producing bacteria in infants. J Pediatr (Rio J) 2017;93:260-6.
  18. Awean GZA, Salameh K, Elmohamed H, Alshmayt H, Omer MRB. Prevalence of ESBL urinary tract infection in children. J Adv Pediatr Child Health 2019;2:004-007.
  19. Hyun HS, Kim JH, Cho MH, Park E, Ha IS, Cheong HI, et al. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. Pediatr Nephrol 2019;34:2399-407.
  20. Kim E, Ahn YH, Lee JW, Park E. Clinical outcomes of non-carbapenem treatment for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Child Kidney Dis 2021;25:22-8.
  21. Jo KJ, Yoo S, Song JY, Kim SH, Park SE. Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli. Pediatr Neonatol 2021;62:271-7.
  22. Chan EY. Community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae in infants less than 2 years of age. Pediatr Nephrol 2022;37:1167-8.
  23. Han KH, Oh MS, Ahn J, Lee J, Kim YW, Yoon YM, et al. Piperacillin-tazobactam versus cefotaxime as empiric treatment for febrile urinary tract infection in hospitalized children. Infect Chemother 2024;56:266-75.
  24. Firoozeh F, Zibaei M, Badmasti F, Khaledi A. Virulence factors, antimicrobial resistance and the relationship between these characteristics in uropathogenic Escherichia coli. Gene Rep 2022;27:101622.
  25. Alyamani EJ, Khiyami AM, Booq RY, Majrashi MA, Bahwerth FS, Rechkina E, et al. The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. Ann Clin Microbiol Antimicrob 2017;16:1.
  26. Cerquetti M, Giufre M, Garcia-Fernandez A, Accogli M, Fortini D, Luzzi I, et al. Ciprofloxacin-resistant, CTX-M-15-producing escherichia coli ST131 clone in extraintestinal infections in Italy. Clin Microbiol Infect 2010;16:1555-8.
  27. Mathers AJ, Peirano G, Pitout JD. Escherichia coli st131: The quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 2015;90:109-54.
  28. Ha JH, Shin JI, Kim KM, Choi JG, Trinh MP, Anh WJ, et al. Prevalence and virulence profiles of ESBL-producing Escherichia coli in urinary and blood infections in South Korea. Folia Microbiol (Praha) 2025;70:589-600.
  29. Kim B, Kim JH, Lee Y. Virulence factors associated with Escherichia coli bacteremia and urinary tract infection. Ann Lab Med 2022;42:203-12. 
  30. Yun KW, Lee MK, Kim W, Lim IS. Uropathogenic escherichia coli ST131 in urinary tract infections in children. Korean J Pediatr 2017;60:221-6.
  31. Uyar Aksu N, Ekinci Z, Dundar D, Baydemir C. Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and empiric therapy. Pediatr Int 2017;59:176-80.
  32. Govindan S, Ravi S, Ekambaram S, Ganesan K. WCN23-0413 Comparison of risk factors, clinical characteristics and short-term clinical outcome of urinary tract infections in children caused by nonESBL and ESBL producing bacteria. Kidney Int Rep 2023;8:S88-9.
  33. Frimodt-Moller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002;19:546-53.
  34. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC, et al. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med 1974;291:1159-63.
  35. Polat M, Kara SS. Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children. Infect Drug Resist 2017;10:393-9.
  36. Polat M, Tapisiz A. Amikacin monotherapy for treatment of febrile urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. Pediatr Infect Dis J 2018;37:378-9.
  37. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007;45:753-60.
  38. Park KS, Kim DR, Baek JY, Shin A, Kim KR, Park H, et al. Susceptibility to fosfomycin and nitrofurantoin of ESBL-positive Escherichia coli and Klebsiella pneumoniae isolated from urine of pediatric patients. J Korean Med Sci 2023;38:e361.